1420996

FORM D		OM	IB APPROVAL
	UNITED STATES	OMB NUMBER:	3235-0076
DDOOFFOOT SECURITIES	S AND EXCHANGE COMMISSION	Expires:	January 31, 2009
	Washington, D.C. 20549	Estimated average burd	
	_	hours per response	4.00
FEB 0 6 2009	Temporary FORM D		
HOMEON DELITEDS	LE OF SECURITIES PURSUANT TO		
HOMSON REUTERS	REGULATION D,		
	ECTION 4(6), AND/OR IMITED OFFERING EXEMPTION		1
Name of Offering ( check if this is an amend	ment and name has changed, and indicate change.)		
Convertible Promissory Notes			SEC Mail Processing
Filing Under (Check box(es) that apply):  Type of Filing:  New Filing  Amendmen	☐ Rule 504 ☐ Rule 505 ■ Rule 506 ☐ Secti	on 4(6) 🗆 ULOE	-1.0//
	A. BASIC IDENTIFICATION DA	TA	JAN 2 1 2009
1. Enter the information requested about the is	suer		Washington, DC
Name of Issuer ( check if this is an amendme	nt and name has changed, and indicate change.)		1:10, DC
Niiki Pharma Inc.			· <del>·</del>
Address of Executive Offices (Number as	nd Street, City, State, Zip Code)	Telephone Number (I	
80 River Street, #5D, Hoboken, NJ 07030	•	201-238-2887	
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (	
Brief Description of Business:			09002261
Research and development company focused	i on anti-cancer compounds		
Type of Business Organization			
■ corporation  ☐ business trust	☐ limited partnership, already formed	☐ other (please specify):	
C) pasiliess trast	☐ limited partnership, to be formed		
Actual or Estimated Date of Incorporation or O	Month Year Presentization 01 2007 ■ Actual	m Carlanaed	
•	-	☐ Estimated	
Jurisdiction of Incorporation of Organization: (	Enter two-letter U.S. Postal Service abbreviation for Stat CN for Canada; FN for other foreign jurisdiction		
GENERAL INSTRUCTIONS			
Federal:			
Who Must File: All issuers making an offering	of securities in reliance on an exemption under Regulati	ion D or Section 4(6), 17 CFR	230.501 et seq. or 15 USC 77d(6).
	than 15 days after the first sale of securities in the offerin is received by the SEC at the address given below or, if the tified mail to that address.		
Where to File: U.S. Securities and Exchange C	Commission, 100 F Street, N.E., Washington, D.C. 20549	).	
Copies Required: Two (2) copies of this notice the manually signed copy or bear typed or print	must be filed with the SEC, one of which must be manued signatures.	rally signed. The copy not ma	nually signed must be photocopy of
Information Required: A new filing must containformation requested in Part C, and any materi SEC.	ain all information requested. Amendments need only re ial changes from the information previously supplied in t	port the name of the issuer and Parts A and B. Part E and the	d offering, any changes thereto, the Appendix need not be filed with the
Filing Fee: There is no federal filing fee.			
that have adopted this form. Issuers relying on If a state requires a payment of a fee as a precor	ance on the Uniform Limited Offering Exemption (ULO) ULOE must file a separate notice with the Securities Ad addition to the claim for the exemption, a fee in the proper The Appendix to the notice constitutes a part of this not	ministrator in each state where r amount shall accompany this	sales are to be, or have been made.
	ATTENTION	·	

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
Enter the information requested for the Each promoter of the issuer, if Each beneficial owner having the Each executive officer and direct Each general and managing particles.	the issuer has be he power to vote ctor of corporate	or dispose, or direct the issuers and of corporate	vote or disposition of, 10°	% or more of a cl	ass of equity securities of the issuer; hip issuers; and
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Sheekhayadayan Uaashmand					
Sheshbaradaran, Hooshmand Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
	•	• • • • • • • • • • • • • • • • • • • •			
c/o Niiki Pharma Inc., 80 River Street, # Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	- I Tomotei	Li Benencial Owner	= Exceptive Officer	- Birecio:	C Coneta: and of Fridaing in Control
Ardakani, Ali Business or Residence Address	(Number and C	Street, City, State, Zip Co.	da)		
Business of Residence Address	(Mumber and 2	street, City, State, Zip Co	ucj		
c/o Niiki Pharma Inc., 80 River Street, #	5D, Hoboken,	NJ 07030			
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Niiki Ventures Inc.					
Business or Residence Address	(Number and S	treet, City, State, Zip Cod	le)		
568 Waters Edge Cres. Apt. 303, West V	lancanver Brit	ich Columbia V7T 042	Canada		
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	DExecutive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	2710,110,00	a Bellottotta o vita			2.0
•					
Zhang, Zhe Business or Residence Address	(Number and S	treet, City, State, Zip Cod	اما		
Dusiness of Residence Address	(Nulliuci and 3	iree, eny, state, zip ede	ic,		
891 Northeliffe Drive, Salt Lake City, U	T 84103				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
McBride, John S.		•			
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
-to Nithal Dhamma Lea On Distant Council M	(SD Usbalian I	N T 07020			
c/o Niiki Pharma Inc., 80 River Street, #	SD, Hobbken,	43 U/U3U			
Check Box(cs) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
	•				
Check Box(es) that Apply:	- D	= DC-1-1 O	5 Farantin Office	D Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	Ocherat and/or tvianaging ratther
Tun Name (Cast name mat, it morrisaar)					
<del></del>	<del></del>				
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	B. INFORMATION ABOUT OFFERING		
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	0	•
2.	Answer also in Appendix, Column 2, if filing under ULOE.  What is the minimum investment that will be accepted from any individual?	S n/a	
۷.	Triat is the minimum diffesiment that will be accepted from any profeturally	Yes	No
3.	Does the offering permit joint ownership of a single unit?	-	Ö
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full Non-	Name (Last name first, if individual)  e.		
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	e of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers  (Check "All States" or check individual States)	All States	
_[A [] [] []	AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA]  [L] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN]  [MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_(ID) _(MO) _(PA) _(PR)
Full	name (Last name first, if individual)		
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	e of Associated Broker or Dealer		
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
^]_ [] () H]	[L] _{IN] _ [IA] _ [KS] _ [KY] _ (LA] _{ ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _{NE] _ [NV] _ {NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ (OH) _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	[ID] [MO] [PA] [PR]
Full l	Name (Last name first, if individual)		
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	e of Associated Broker or Dealer		
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers	·	···
	(Check "All States" or check individual States)	All States	
_[A _[] [M [F	IL] _ [IN] _ [IA] _ [KS] _ (KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	[ID] [MO] [PA] [PR]

## C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\pi\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	s
	Equity	\$	s
	□ Common □ Preferred		
	Convertible Securities (including warrants)	S_3,000,000	\$ 50,000
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$_3,000,000	\$ 500,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	2	\$ <u>500,000</u>
	Non-accredited Investors		s
	Total (for filings under Rule 504 only)		s
	Answer also in Appendix, Column 4, if filing under ULOE		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Dollar Amount Sold
	Type of offering		· \$
	Rule 505		s
	Regulation A	************	\$
	Rule 504	-	<b>3</b>
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	0	\$
	Printing and Engraving Costs	0	\$
	Legal Fees	•	\$ 25,000
	Accounting Fees	0	s
	Engineering Fees	o	s
	Sales Commissions (specify finders' fees separately)		s
	Other Expenses (identify)	0	\$
	Total		\$ 25,000
	• • • • • • • • • • • • • • • • • • •		·

b. Enter the difference between the aggregate offering price given in response to Part C - 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."	e 		s	2,975,000
Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to for each of the purposes shown. If the amount for any purpose is not known, furnish an eand check the box to the left of the estimate. The total of the payments listed must equal adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above.	stimate the			
		Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees	0	\$	0	\$
Purchase of real estate	Ġ	\$		\$
Purchase, rental or leasing and installation of machinery and equipment		\$	ם	s
Construction or leasing of plant buildings and facilities	D	\$	Ó	\$
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	0	<b>s</b>	o	s
Repayment of indebtedness	_	\$	0	s
Working capital	 D	\$		\$_2,975,000
Other (specify):	_ 0	\$	0	s
	- -	\$	D	\$
Column Totals	۵	\$	•	\$ 2,975,000
Total Payments Listed (column totals added)		<b>a</b> \$ <u>2,975,000</u>		-
D. FEDERAL SIGNAT	URE			

Signature

Niiki Pharma Inc.

Name of Signer (Print or Type)

Hooshmand Sheshbaradaran

Signature

Hooshmand Sheshbaradaran

Signature

Hooshmand Sheshbaradaran

Date

January 1, 2009

Title of Signer (Print or Type)

President and Chief Executive Officer

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

